Abbott India

When is the next results date for Abbott India?

No Upcoming Board Meetings

Has Abbott India declared dividend?

Yes, Abbott India Ltd. has declared a dividend of 410% (₹410 per share) with an ex-date of July 19, 2024, resulting in a dividend yield of 1.3%. The company has shown strong total returns over various periods, with a total return of 104.28% over the last 4 years.

Abbott India Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 4100%<BR>- Amount per share: 410 per share<BR>- Ex-date: 19 Jul 24<BR><BR>Dividend Yield: 1.3%<BR><BR>Total Returns by Period:<BR>In the last 6 months, Abbott India experienced a price return of 9.35% with no dividend return, resulting in a total return of 9.35%.<BR><BR>Over the past year, the company achieved a price return of 17.76% and a dividend return of 1.46%, leading to a total return of 19.22%.<BR><BR>In the 2-year period, Abbott India saw a price return of 45.62% and a dividend return of 2.56%, culminating in a total return of 48.18%.<BR><BR>For the 3-year period, the price return was 79.7% with a dividend return of 4.01%, resulting in a total return of 83.71%.<BR><BR>In the last 4 years, the company recorded a price return of 99.09% and a dividend return of 5.19%, achieving a total return of 104.28%.<BR><BR>Over the 5-year period, Abbott India had a price return of 86.07% and a dividend return of 6.21%, leading to a total return of 92.28%.<BR><BR>Overall, Abbott India has declared a substantial dividend, and the total returns across various periods indicate strong performance, particularly in price appreciation. The combination of high dividend yield and significant total returns reflects positively on the company's financial health.

Who are the peers of the Abbott India?

Abbott India's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Alkem Lab, GlaxoSmithKline Pharma, Glenmark Pharma, Biocon, and Ipca Labs. In terms of management risk, growth ratings, and capital structure, Abbott India ranks well, with a 1-year return of 19.13%, lower than Divi's Lab's 51.96% but higher than Alkem Lab's 3.75%.

Peers: Abbott India's peers are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Alkem Lab, Glaxosmi. Pharma, Glenmark Pharma, Biocon, and Ipca Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Dr Reddy's Labs, and Glaxosmi. Pharma, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Alkem Lab, and Ipca Labs, and Average management risk is present at Glenmark Pharma and Biocon. Growth ratings show Excellent growth at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is noted at Abbott India and Ipca Labs, and Below Average growth is seen at Divi's Lab., Torrent Pharma, Alkem Lab, Glaxosmi. Pharma, Glenmark Pharma, and Biocon. Capital Structure is Excellent for Abbott India, Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Alkem Lab, and Glaxosmi. Pharma, Good for Glenmark Pharma, and Below Average for Biocon.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Alkem Lab has the lowest at 3.75%. Abbott India's 1-year return of 19.13% is higher than Alkem Lab's but lower than Divi's Lab.'s. Additionally, Torrent Pharma, Alkem Lab, Glenmark Pharma, and Biocon have negative six-month returns.

Is Abbott India overvalued or undervalued?

As of October 27, 2022, Abbott India is considered very expensive with a PE ratio of 47.32 and other high valuation metrics, indicating it is overvalued compared to peers like Sun Pharma and Cipla, despite its recent strong performance against the Sensex.

As of 27 October 2022, Abbott India's valuation grade moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently overvalued, with a PE ratio of 47.32, a Price to Book Value of 19.01, and an EV to EBITDA of 38.88. These ratios suggest that investors are paying a premium for the stock compared to its earnings and book value.<BR><BR>In comparison to its peers, Abbott India's valuation stands out as particularly high; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla is valued more attractively with a PE of 22.99. Additionally, Abbott's PEG ratio of 2.67 further emphasizes its overvaluation relative to peers like Divi's Lab, which has a PEG of 2.15. Despite outperforming the Sensex over various periods, including a 16% return over the past year compared to the Sensex's 7.63%, the current valuation metrics suggest that investors may be overestimating Abbott India's growth potential.

Who are in the management team of Abbott India?

As of March 2023, Abbott India's management team includes Munir Shaikh (Chairman), Vivek Vasudev Kamath (Managing Director), and several non-executive and independent directors, overseeing the company's strategic direction and governance.

As of March 2023, the management team of Abbott India includes the following members:<BR><BR>1. Munir Shaikh - Chairman (Non-Executive)<BR>2. Kaiyomarz Marfatia - Non Executive Director<BR>3. Ambati Venu - Non Executive Director<BR>4. Anisha Motwani - Independent Director<BR>5. Sudarshan Jain - Independent Director<BR>6. Shalini Kamath - Independent Director<BR>7. Sabina Ewing - Non Executive Director<BR>8. Vivek Vasudev Kamath - Managing Director<BR>9. Mahadeo Karnik - Director<BR><BR>This team is responsible for overseeing the company's strategic direction and governance.

What does Abbott India do?

Abbott India Ltd. is a leading multinational pharmaceutical company in India, with recent net sales of ₹16,046 Cr and a net profit of ₹3,670 Cr as of March 2025. It has a market cap of ₹73,197 Cr and key metrics include a P/E ratio of 51.00 and a dividend yield of 1.19%.

Overview: <BR>Abbott India Ltd. is a leading multinational pharmaceutical company in India, categorized as a Large Cap in the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Abbott India Ltd. was incorporated in an unspecified year and has maintained its status as a prominent player in the pharmaceutical sector. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Most recent Net Sales: 16,046 Cr (Quarterly Results - Mar 2025) <BR>- Most recent Net Profit: 3,670 Cr (Quarterly Results - Mar 2025) <BR>- Market-cap value: INR 73,197 Cr (Large Cap) <BR><BR>Key Metrics: <BR>- P/E: 51.00 <BR>- Industry P/E: 37 <BR>- Dividend Yield: 1.19% <BR>- Debt-Equity: -0.30 <BR>- Return on Equity: 40.17% <BR>- Price to Book: 20.72 <BR><BR>Contact Details: <BR>Address: Unit No 3 Corporate Park, Sion Trombay Road Chembur Mumbai Maharashtra : 400071 <BR>Tel: 91-22-67978888/50461000/2000/1119 <BR>Email: investorrelations.india@abbott.com <BR>Website: http://www.abbott.co.in

Who are the top shareholders of the Abbott India?

The top shareholder of Abbott India is Abbott Capital India Limited, holding 50.44%. Other significant shareholders include mutual funds with 7.77%, SBI Large & Midcap Fund at 2.66%, and individual investors with a combined 13.35%.

The top shareholders of Abbott India include Abbott Capital India Limited, which holds the largest stake at 50.44%. The company also has a diverse range of shareholders, including mutual funds, with 35 schemes collectively holding 7.77%. Additionally, there are 12 foreign institutional investors (FIIs) that hold 0.16% of the shares. The highest public shareholder is the SBI Large & Midcap Fund, which owns 2.66%. Individual investors collectively hold 13.35% of the company's shares.

How big is Abbott India?

As of 24th July, Abbott India Ltd. has a market capitalization of 73,832.00 Cr, with recent net sales of 6,409.15 Cr and a net profit of 1,414.44 Cr. The company has shareholder's funds of 4,233.15 Cr and total assets of 5,902.35 Cr as of March 2025.

As of 24th July, Abbott India Ltd. has a market capitalization of 73,832.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Abbott India reported Net Sales of 6,409.15 Cr and a Net Profit of 1,414.44 Cr.<BR><BR>For the latest annual period ending in March 2025, the company has Shareholder's Funds amounting to 4,233.15 Cr and Total Assets of 5,902.35 Cr.

How has been the historical performance of Abbott India?

Abbott India has shown consistent growth from March 2020 to March 2025, with net sales increasing from 4,093.14 crore to 6,409.15 crore, and profit after tax rising from 592.93 crore to 1,414.44 crore. Key financial metrics, including operating profit and earnings per share, have also significantly improved during this period.

Answer:<BR>Abbott India's historical performance shows a consistent growth trend in net sales, operating profit, and profit after tax over the past several years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Abbott India has demonstrated strong growth in net sales, increasing from 4,093.14 crore in March 2020 to 6,409.15 crore in March 2025. The total operating income followed a similar upward trajectory, reaching 6,409.15 crore in March 2025, up from 4,093.14 crore in March 2020. Operating profit (PBDIT) also saw significant growth, rising from 870.84 crore in March 2020 to 1,970.18 crore in March 2025. Profit before tax increased from 802.70 crore in March 2020 to 1,886.95 crore in March 2025, while profit after tax rose from 592.93 crore to 1,414.44 crore during the same period. The company's earnings per share (EPS) improved markedly from 279.03 in March 2020 to 665.62 in March 2025. Total assets grew from 3,532.41 crore in March 2020 to 5,902.35 crore in March 2025, reflecting a robust balance sheet. Cash flow from operating activities increased from 626.00 crore in March 2020 to 1,011.00 crore in March 2025, indicating strong operational efficiency. Overall, Abbott India has shown a solid financial performance with consistent growth across key metrics over the years.

Is Abbott India technically bullish or bearish?

As of December 2, 2025, the technical trend has shifted to a bearish stance, driven by bearish indicators like the weekly MACD and Bollinger Bands, despite some bullish momentum in the weekly RSI.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include the weekly MACD and Bollinger Bands both indicating bearish conditions, alongside bearish moving averages on the daily timeframe. Although the weekly RSI shows bullish momentum, it is overshadowed by the overall bearish signals from other indicators. The Dow Theory presents a mildly bullish view on the weekly chart, but this is not enough to counter the prevailing bearish trend.

Are Abbott India Ltd. latest results good or bad?

Abbott India Ltd.'s latest Q4 FY26 results are mixed; while net profit rose by 7.60% and net sales grew by 6.54%, there was a sequential decline in sales of 0.84%, raising concerns about future demand and growth sustainability. Investors should consider both the strong profitability and the challenges in revenue growth.

Abbott India Ltd.'s latest results for Q4 FY26 can be considered mixed, with some positive aspects but also areas of concern. <BR><BR>On the positive side, the company reported a net profit of ₹394.93 crore, which reflects a year-on-year increase of 7.60%. Additionally, net sales reached ₹1,709.51 crore, marking a 6.54% growth compared to the same quarter last year. The operating margin improved to 28.13%, up 142 basis points from the previous year, indicating effective cost management and pricing power.<BR><BR>However, there are notable challenges as well. The sequential decline in net sales of 0.84% from the previous quarter suggests potential headwinds in demand momentum. This decline is concerning, especially as the pharmaceutical sector typically sees seasonal growth in the final quarter. Furthermore, while the full fiscal year FY26 showed an overall sales increase of 8.11%, the growth rate still lags behind broader sector averages.<BR><BR>In summary, while Abbott India demonstrates strong profitability and margin expansion, the modest revenue growth and recent sequential decline raise questions about future demand and growth sustainability. Investors may need to weigh these factors carefully when assessing the company's performance.

Which are the latest news on Abbott India?

Should I buy, sell or hold Abbott India Ltd.?

Why is Abbott India Ltd. falling/rising?

As of 13-May, Abbott India Ltd. is seeing a stock price increase to 27,261.25, up 1.35%, driven by strong investor interest and outperforming the sector. Despite a year-to-date decline, recent gains and rising trading activity suggest a positive shift in investor sentiment.

As of 13-May, Abbott India Ltd. is experiencing a rise in its stock price, currently at 27,261.25, reflecting an increase of 363.15 (1.35%). This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.78% today and opened with a significant gain of 3.91%. Additionally, it reached an intraday high of Rs 27,949.95, indicating strong investor interest.<BR><BR>The stock's performance over the past week shows a gain of 3.67%, contrasting sharply with the Sensex, which has declined by 4.30% during the same period. Over the past month, Abbott India Ltd. has increased by 5.97%, while the Sensex has fallen by 2.91%. This trend suggests that the stock is gaining traction among investors despite broader market challenges.<BR><BR>Moreover, there is rising investor participation, as evidenced by a 3.76% increase in delivery volume compared to the 5-day average. The stock's liquidity is also favorable, being liquid enough for a trade size of Rs 1.41 crore. The company's strong management efficiency, highlighted by a high return on equity (ROE) of 34.23%, and its net-debt-free status further bolster investor confidence.<BR><BR>However, it is important to note that the stock has underperformed over the longer term, with a year-to-date decline of 6.22% and a one-year drop of 10.48%. Despite this, the recent performance indicates a positive shift, driven by strong trading activity and investor sentiment.